ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the appointment of Pierre Legault to its Board of Directors. Mr. Legault will serve as Chairman of the Audit Committee.
“Pierre is an experienced executive and board member who has extensive knowledge of the biotechnology and pharmaceutical industry and the finance function in both private and publically traded companies,” said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO. “We look forward to having Pierre lead our Audit Committee and believe his expertise will complement our board as ARMO continues to evolve into a later-stage immuno-oncology company.”